Resiquimod, a TLR7/8 agonist, induces dendritic cell-like differentiation in DNMT3A mutant AML cells and provides Dnmt3amut /Flt3mut AML mice to provide a survival advantage. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.